PortViewPortView
CareDx, Inc logo

CareDx, Inc (CDNA) Stock Analysis

NASDAQHealthcareMedical - Diagnostics & Research

$48.93-0.08%
1-year price historyRange $12.73 – $52.36
52-week range$48.93
$12.37$53.67

What CareDx, Inc does

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Key metrics

Market cap
$2.53B
P/E (TTM)
58.25
EPS (TTM)
$0.84
Beta
2.42
Dividend yield
0.00%
Revenue / share
$8.90
50-day avg
$39.31
200-day avg
$24.55
52-week high
$53.67
52-week low
$12.37
CEO
John Walter Hanna Jr.

ETFs linked to CDNA

Broad-market and Healthcare sector ETFs an investor holding CareDx, Inc is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CDNA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze CDNA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for CareDx, Inc?
CareDx, Inc trades under the ticker CDNA on NASDAQ.
Which exchange is CDNA listed on?
CDNA is listed on NASDAQ.
What sector does CareDx, Inc operate in?
CareDx, Inc is classified in the Healthcare sector (Medical - Diagnostics & Research industry).
How can PortView help analyze CDNA in a portfolio?
PortView shows CDNA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.